TNFRSF8 and peripheral T-cell lymphoma, not otherwise specified: Potentially, our discovery may provide the basis for the use of brentuximab vedotin (an anti-CD30 antibody–drug conjugate), which has recently been used in a successful phase III trial for patients with CD30-positive peripheral T-cell lymphomas, in this subgroup of NKTL patients to improve survival [46].